HRP20231356T1 - Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže - Google Patents
Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže Download PDFInfo
- Publication number
- HRP20231356T1 HRP20231356T1 HRP20231356TT HRP20231356T HRP20231356T1 HR P20231356 T1 HRP20231356 T1 HR P20231356T1 HR P20231356T T HRP20231356T T HR P20231356TT HR P20231356 T HRP20231356 T HR P20231356T HR P20231356 T1 HRP20231356 T1 HR P20231356T1
- Authority
- HR
- Croatia
- Prior art keywords
- rodent
- heavy chain
- human
- constant region
- region
- Prior art date
Links
- 241000283984 Rodentia Species 0.000 title claims 23
- 241001465754 Metazoa Species 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000009261 transgenic effect Effects 0.000 claims 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (9)
1. Transgeni glodavac, te glodavac u svojoj zametnoj liniji sadrži lokus imunoglobulina teškog lanca koji sadrži, u redoslijedu od 5' do 3', genske segmente ljudskog nepreuređenog teškog lanca varijabilnosti (V), raznolikosti (D) i regije spajanja (J), konstantnu regiju teškog lanca glodavca i 3' pojačivač štakora koji sadrže sekvencu navedenu kao SEQ ID NO:1, pri čemu lokus imunoglobulina teškog lanca ne sadrži gen konstantne regije ljudskog imunoglobulina, i pri čemu je glodavac miš ili štakor.
2. Glodavac prema zahtjevu 1, naznačen time što su genski segmenti ljudskog teškog lanca varijabilnosti, raznolikosti i regije spajanja sadržani na segmentu DNA koji je oko 50 do 500 kb ili veći, ili pri čemu su genski segmenti human ljudskog teškog lanca varijabilnosti, raznolikosti i regije spajanja sadržani na segmentu DNA koji ima do 2 megabaze.
3. Glodavac prema zahtjevu 1 ili zahtjevu 2, naznačen time što je glodavac štakor.
4. Glodavac prema bilo kojem od zahtjeva 1 do 3, naznačen time što je konstantna regija teškog lanca glodavca Fc regija glodavca.
5. Postupak za proizvodnju protutijela koje ima ljudsku varijabilnu regiju i konstantnu regiju glodavca koji se sastoji od izlaganja transgenog glodavca antigenu, pri čemu glodavac u svojoj zametnoj liniji sadrži lokus imunoglobulina teškog lanca koji sadrži, u 5' do 3' redoslijedu, genske segmente ljudskog nepreuređenog teškog lanca varijabilnosti (V), raznolikosti (D) i regije spajanja, konstantnu regiju teškog lanca glodavca, te 3' pojačivač štakora koji sadrže sekvencu navedenu kao SEQ ID NO:1, pri čemu lokus imunoglobulina teškog lanca ne sadrži gen konstantne regije ljudskog imunoglobulina, pri čemu je izloženost antigenu takva da transgeni glodavac proizvodi protutijelo za antigen, pri čemu protutijelo ima varijabilnu regiju teškog lanca čovjeka i konstantnu regiju teškog lanca glodavca, te pri čemu glodavac je miš ili štakor.
6. Postupak prema zahtjevu 5, naznačen time što su genski segmenti ljudskog teškog lanca varijabilnosti, raznolikosti i regije spajanja sadržani na segmentu DNA koji je oko 50 do 500 kb ili veći, ili pri čemu su genski segmenti ljudskog teškog lanca varijabilnosti, raznolikosti i regije spajanja sadržani na segmentu DNA koji ima do 2 megabaze.
7. Postupak prema zahtjevu 5 ili zahtjevu 6, naznačen time što je glodavac štakor.
8. Postupak prema bilo kojem od zahtjeva 5 do 7, naznačen time što je konstantna regija teškog lanca glodavca Fc regija glodavca.
9. Postupak prema bilo kojem od zahtjeva 5 do 8, naznačen time što dalje obuhvaća korak izrade hibridoma iz transgenog glodavca, te hibridom sadrži DNA koja kodira protutijelo, pri čemu je hibridom napravljen iz slezene transgenog glodavca.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737371P | 2012-12-14 | 2012-12-14 | |
| EP19204021.0A EP3653049B1 (en) | 2012-12-14 | 2013-12-13 | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231356T1 true HRP20231356T1 (hr) | 2024-02-16 |
Family
ID=50935093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231356TT HRP20231356T1 (hr) | 2012-12-14 | 2013-12-13 | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
| HRP20201160TT HRP20201160T1 (hr) | 2012-12-14 | 2020-07-24 | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201160TT HRP20201160T1 (hr) | 2012-12-14 | 2020-07-24 | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9475859B2 (hr) |
| EP (3) | EP2931030B2 (hr) |
| JP (1) | JP6705650B2 (hr) |
| KR (3) | KR20210040189A (hr) |
| CN (2) | CN110042105B (hr) |
| AU (2) | AU2013358958B2 (hr) |
| CA (1) | CA2895144C (hr) |
| CY (1) | CY1123215T1 (hr) |
| DK (2) | DK2931030T4 (hr) |
| ES (2) | ES2813609T3 (hr) |
| FI (2) | FI3653049T3 (hr) |
| HR (2) | HRP20231356T1 (hr) |
| HU (2) | HUE064063T2 (hr) |
| IL (2) | IL239300B (hr) |
| LT (2) | LT2931030T (hr) |
| PL (1) | PL3653049T3 (hr) |
| PT (2) | PT2931030T (hr) |
| SG (1) | SG11201504676VA (hr) |
| SI (2) | SI2931030T1 (hr) |
| WO (1) | WO2014093908A2 (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
| US10993420B2 (en) * | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| PT3209698T (pt) | 2014-10-22 | 2018-12-14 | Crescendo Biologics Ltd | Ratinhos transgénicos |
| MX2017008190A (es) * | 2014-12-19 | 2018-03-23 | Regeneron Pharma | Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa. |
| CN107921128B (zh) | 2015-08-05 | 2022-04-26 | 詹森生物科技公司 | 抗cd154抗体及其使用方法 |
| PL3337824T3 (pl) | 2015-08-17 | 2021-04-19 | Janssen Pharmaceutica Nv | Przeciwciała anty-bcma, bispecyficzne cząsteczki wiążące antygen, które wiążą bcma i cd3, oraz ich zastosowania |
| AU2016329057A1 (en) | 2015-09-30 | 2018-04-12 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human CD40 and methods of use |
| CA3003899A1 (en) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
| AU2017272337C1 (en) | 2016-06-03 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| CN109641049B (zh) * | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| WO2018095932A1 (en) * | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| AU2017365367A1 (en) * | 2016-11-22 | 2019-05-30 | Merck Patent Gmbh | Monoclonal antibody directed to FGFR1 |
| CN110662421B (zh) * | 2017-01-19 | 2023-03-24 | 欧莫诺艾比公司 | 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体 |
| JP7303126B2 (ja) | 2017-06-20 | 2023-07-04 | テネオバイオ， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| AU2018392088A1 (en) | 2017-12-22 | 2020-08-13 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| US11591399B2 (en) | 2018-02-14 | 2023-02-28 | Abba Therapeutics Ag | Anti-human PD-L2 antibodies |
| CN116874591A (zh) | 2018-03-24 | 2023-10-13 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途 |
| JP7411575B2 (ja) | 2018-05-11 | 2024-01-11 | ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド | Ｏｘ４０に対する完全ヒト抗体、それを調製する方法、およびその使用 |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| JOP20200302A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | الأجسام المضادة لـ cd3 واستخداماتها |
| PE20210634A1 (es) | 2018-05-24 | 2021-03-23 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| US20190380316A1 (en) | 2018-06-14 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of engineered dh-dh rearrangement and uses thereof |
| CA3125380A1 (en) * | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
| AU2020291938A1 (en) | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
| JP2022541332A (ja) | 2019-07-26 | 2022-09-22 | ヤンセン バイオテツク，インコーポレーテツド | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| CN114174346A (zh) | 2019-07-26 | 2022-03-11 | 詹森生物科技公司 | 抗hk2嵌合抗原受体(car) |
| WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
| AU2020359070A1 (en) | 2019-10-03 | 2022-04-21 | Janssen Biotech, Inc. | Methods for producing biotherapeutics with increased stability by sequence optimization |
| EP4069722A1 (en) | 2019-12-02 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| EP4121172A1 (en) | 2020-04-29 | 2023-01-25 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Treatment methods for multiple myeloma |
| MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
| CA3190307A1 (en) | 2020-07-29 | 2022-02-03 | Janssen Biotech, Inc. | Proteins comprising hla-g antigen binding domains and their uses |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
| EP4051700A1 (en) | 2020-12-23 | 2022-09-07 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| MX2023008803A (es) | 2021-01-27 | 2023-08-04 | Janssen Biotech Inc | Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos. |
| WO2023144723A1 (en) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
| WO2024064714A2 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Antibodies that bind cd228 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4977081A (en) | 1987-05-04 | 1990-12-11 | Adi Diagnostics, Inc. | Stable rabbit-mouse hybridomas and secretion products thereof |
| ATE175234T1 (de) | 1990-07-10 | 1999-01-15 | Nippon Kokan Kk | Geflügelspezifischen immunglobulin g produzierende hybridomas |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0814159B1 (en) * | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| JPH08140528A (ja) * | 1993-12-03 | 1996-06-04 | Genpharm Internatl Inc | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| WO1997016537A1 (en) | 1995-10-30 | 1997-05-09 | Spectral Diagnostics, Inc. | Stable chicken b-cell line and method of use thereof |
| US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
| EP0942968B1 (en) * | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
| ES2679282T3 (es) * | 2004-10-22 | 2018-08-23 | Revivicor Inc. | Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena |
| CA2638117A1 (en) | 2006-01-25 | 2007-08-30 | Erasmus University Medical Center Rotterdam | Generation of heavy-chain only antibodies in transgenic animals |
| EP2505058A1 (en) * | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| AU2008259939B2 (en) * | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| PL2564695T3 (pl) * | 2009-07-08 | 2015-10-30 | Kymab Ltd | Modele zwierzęce i cząsteczki terapeutyczne |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| WO2011158009A1 (en) * | 2010-06-17 | 2011-12-22 | Kymab Limited | Animal models and therapeutic molecules |
| EP2638155A1 (en) | 2010-11-08 | 2013-09-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
-
2013
- 2013-12-13 DK DK13843056.6T patent/DK2931030T4/da active
- 2013-12-13 PT PT138430566T patent/PT2931030T/pt unknown
- 2013-12-13 HU HUE19204021A patent/HUE064063T2/hu unknown
- 2013-12-13 JP JP2015548018A patent/JP6705650B2/ja active Active
- 2013-12-13 SI SI201331758T patent/SI2931030T1/sl unknown
- 2013-12-13 WO PCT/US2013/075157 patent/WO2014093908A2/en active Application Filing
- 2013-12-13 AU AU2013358958A patent/AU2013358958B2/en active Active
- 2013-12-13 PL PL19204021.0T patent/PL3653049T3/pl unknown
- 2013-12-13 FI FIEP19204021.0T patent/FI3653049T3/fi active
- 2013-12-13 LT LTEP13843056.6T patent/LT2931030T/lt unknown
- 2013-12-13 HR HRP20231356TT patent/HRP20231356T1/hr unknown
- 2013-12-13 SG SG11201504676VA patent/SG11201504676VA/en unknown
- 2013-12-13 ES ES13843056T patent/ES2813609T3/es active Active
- 2013-12-13 CN CN201910018228.6A patent/CN110042105B/zh active Active
- 2013-12-13 KR KR1020217009938A patent/KR20210040189A/ko not_active Application Discontinuation
- 2013-12-13 CA CA2895144A patent/CA2895144C/en active Active
- 2013-12-13 KR KR1020227009366A patent/KR20220041953A/ko not_active Application Discontinuation
- 2013-12-13 EP EP13843056.6A patent/EP2931030B2/en active Active
- 2013-12-13 FI FIEP13843056.6T patent/FI2931030T4/fi active
- 2013-12-13 CN CN201380070457.3A patent/CN104994729B/zh active Active
- 2013-12-13 ES ES19204021T patent/ES2963516T3/es active Active
- 2013-12-13 PT PT192040210T patent/PT3653049T/pt unknown
- 2013-12-13 EP EP19204021.0A patent/EP3653049B1/en active Active
- 2013-12-13 KR KR1020157018403A patent/KR102239125B1/ko active IP Right Grant
- 2013-12-13 DK DK19204021.0T patent/DK3653049T3/da active
- 2013-12-13 HU HUE13843056A patent/HUE050930T2/hu unknown
- 2013-12-13 LT LTEP19204021.0T patent/LT3653049T/lt unknown
- 2013-12-13 SI SI201332063T patent/SI3653049T1/sl unknown
- 2013-12-13 EP EP23188538.5A patent/EP4269602A3/en active Pending
-
2014
- 2014-10-17 US US14/517,755 patent/US9475859B2/en active Active
-
2015
- 2015-06-09 IL IL239300A patent/IL239300B/en active IP Right Grant
-
2016
- 2016-10-24 US US15/332,583 patent/US10385132B2/en active Active
-
2018
- 2018-08-31 AU AU2018223041A patent/AU2018223041B2/en active Active
-
2020
- 2020-07-24 HR HRP20201160TT patent/HRP20201160T1/hr unknown
- 2020-07-29 CY CY20201100706T patent/CY1123215T1/el unknown
- 2020-12-23 IL IL279716A patent/IL279716A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231356T1 (hr) | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže | |
| HRP20191333T1 (hr) | Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost | |
| SI2883449T1 (en) | Light-chain modified antibodies with histidine and genetically modified rodents for their production | |
| HRP20230490T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| HRP20191680T1 (hr) | Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
| HRP20160497T1 (hr) | Mišji hibridni laki lanac | |
| HRP20191233T1 (hr) | Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih | |
| HRP20220205T1 (hr) | Transgena mišja životinja koja proizvodi antitijela | |
| Shi et al. | Comparative analysis of human and mouse immunoglobulin variable heavy regions from IMGT/LIGM-DB with IMGT/HighV-QUEST | |
| HRP20171193T1 (hr) | Proizvodnja vezivnih molekula | |
| JP2015502177A5 (hr) | ||
| JP2016127840A5 (hr) | ||
| JP2015505477A5 (hr) | ||
| RU2012128856A (ru) | Мыши, которые производят антитела, имеющие только тяжелую цепь | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| HRP20192255T1 (hr) | Humanizirani miševi s univerzalnim lakim lancem | |
| JP2011182801A5 (hr) | ||
| HRP20192311T1 (hr) | Adam6 miševi | |
| JP2020530760A5 (hr) | ||
| HRP20220888T1 (hr) | Ne-humane životinje koje imaju konstruirani lokus imunoglobulinskog lamba lakog lanca | |
| AR045563A1 (es) | Anticuerpos dirigidos a m-csf | |
| AR053514A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
| RU2015155601A (ru) | Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки | |
| Lefranc et al. | IMGT® and 30 years of Immunoinformatics insight in antibody V and C domain structure and function |